LTT Bio-Pharma’s predecessor, LTT Research Institute was founded as a bio-venture from St. Marianna University School of Medicine in 1988. Since then, we have continued new drug development over close to 30 years. Our management philosophy is application of state-of-the-art science and technology to the medicines to improve the health and lives of people in all over the world.
Dr. Yutaka Mizushima, the first chairman of director, CTO and founder, is a pioneer in drug delivery systems (DDS) research in Japan. He has led to the success a lot of new drug development, such as Lipo-PGE1. He also contributed as a professor (a director of Institute of Medical Science, St. Marianna University School of Medicine), a member of the House of Councilors, and parliamentary secretary of Education, Culture, Sports, Science Technology Ministry. He also founded the Beijing Tide Pharma in collaboration with the Chinese government-based hospital in 1995, which have developed a number of new drugs, including the Lipo-PGE1.
Toru Mizushima, who was appointed to the second chairman of director and CTO also has served as a professor over a long time (a director of Institute of Drug discovery and development, Kumamoto University). He spread the drug re-positioning (DR) in our country. Also currently, he is the vice president of Beijing Tide Pharma and performed drug development in China.
As you can see from the history of LTT, we have many features and properties listed below.

  • ① the world’s leading core original technology for efficient drug discovery techniques, DDS and DR
  • ② human network spread in industry, academia and government (in particular, academia)
  • ③ strong ties to Beijing Tide Pharma, which has grown to the China’s leading pharmaceutical companies (among the best 20 in the profits)
  • ④ trust based on the continued performance of the company and the accumulated drug discovery know-hows (experienced employees and executives)

In 2016, we began a new attempt (see the features of our research and development). All these attempts are those that take advantage of the company’s assets as described above.
It is due to supports from shareholders, related organizations (government, universities, medical institutions and other companies) and many people (employees) that LTT could continue the drug discovery over the long time so far. To answer to this appreciation, LTT will continue to effort for future further development of excellent drugs. We expect more support from everyone.

Tohru Mizushima, Ph. D.,
Chairman of Director・Chief Technology Officer